"Genentech’s commitment to basic biology and innovation is fundamental to novel drug development."
I joined Genentech in 2016. Prior to Genentech, I was a faculty member at the University of Chicago studying immune tolerance and autoimmune disease. I was fascinated by tumor immunology as tumors represent a unique “self” to the immune system. The recent success of cancer immunotherapy has been revolutionizing the field, and I was thrilled to join Genentech to develop novel immunotherapies that could have direct impact on patients.
Cell Rep. 2016 Oct 4;17(2):387-398.